// App-Quantinova.ai

P2-05-19 : Impact of TP53 functional mutation type on clinical outcomes of advanced breast cancer patients

Researchers

Presenter

  • N Stjepanovic

Principal Investigators

  • S Garg

  • H Berman

  • D Warr

  • E Amir

  • D Cescon

  • C Elser

  • L Wang

  • S Kamel-Reid

  • L Siu

  • PL Bedard

  • T Stockley

Medical Centers

  • Princess Margaret Cancer Center, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Triple-negative breast cancer

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • erb-b2 receptor tyrosine kinase 2

  • Transthyretin

  • Tumor protein p53

Drug/Treatment

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01505400

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved